Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Monoclonal antibodies Stories

2013-11-12 23:25:17

Reportbuyer.com just published a new market research report: Psoriasis Treatment: World Drug Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues. Avoid falling...

2013-11-07 23:34:32

A new randomized, controlled trial(RCT) is the fourth RCT to provide evidence for the efficacy of etanercept for intervertebral disc-related pain. The first human data regarding the effectiveness of etanercept for sciatica was reported by the Institute of Neurological Recovery more than a decade earlier. Los Angeles, California (PRWEB) November 07, 2013 A new randomized clinical trial (RCT) published in the November 1, 2013 issue of the journal Spine (1) provides new evidence for the...

2013-11-07 23:30:39

RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store. Dallas, TX (PRWEB) November 07, 2013 The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of...

2013-11-07 08:32:43

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that data from its ongoing Phase 1 trial of KB004, an anti-EphA3 monoclonal antibody (mAb), will be presented at a poster session at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exhibition. The Phase 1 trial of KB004 is a multi-center, dose-escalation study evaluating KB004 in patients with advanced hematologic malignancies. The presentation will...

2013-11-05 08:34:27

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development collaboration with The Scripps Research Institute (TSRI) of La Jolla, CA. Under the terms of the agreement, Sorrento obtains an exclusive, worldwide license to TSRI's novel technologies based on ghrelin signaling inhibition for the prevention and treatment of obesity and other metabolic disorders. A research group...

2013-11-04 04:21:58

BREDA, The Netherlands and GHENT, Belgium, November 4, 2013 /PRNewswire/ -- arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties will closely collaborate to use arGEN-X' SIMPLE Antibody(TM) technology in validating the biology of a novel cancer immunomodulation target and creating functional leads with therapeutic potential. arGEN-X has an option to develop and commercialize...

2013-10-31 12:27:22

-- Results presented as late breaker at American College of Rheumatology -- LAKE FOREST, Ill., Oct. 31, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, this week shared the results of two open-label extension studies of CT-P13 (infliximab), one in patients with rheumatoid arthritis, the other in patients with ankylosing spondylitis, which were presented at the 2013 American College of Rheumatology (ACR)/Association of...

2013-10-31 12:27:00

Small trial, combining anti-allergy medication and desensitization method, could change clinical approach for patients with severe peanut allergies BOSTON, Oct. 31, 2013 /PRNewswire-USNewswire/ -- A pilot study from Boston Children's Hospital's Division Allergy and Immunology and Harvard Medical School shows that desensitizing peanut allergic patients through increased peanut exposure, in tandem with an allergy drug called omalizumab (Xolair®, anti-IgE monoclonal antibody,...

2013-10-30 16:25:11

SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) today announced the closing of its previously announced underwritten public offering. The gross proceeds to Sorrento from the offering, including the previously announced exercise of the over-allotment option by the underwriters, are $34.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sorrento. Sorrento intends to use the net...

2013-10-30 15:40:18

Berkeley Lab researchers take cues from nature in designing a programmable nanomaterial for biosensing Taking inspiration from the human immune system, researchers at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have created a new material that can be programmed to identify an endless variety of molecules. The new material resembles tiny sheets of Velcro, each just one-hundred nanometers across. But instead of securing your sneakers, this molecular...